Navigation Links
First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Date:2/11/2009

Findings Support Development for Chronic Pain Indications

LA JOLLA, Calif., Feb. 11 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that oral administration of NGX426, an AMPA/kainate-type glutamate receptor antagonist, was safe and well-tolerated in healthy male and female subjects when dosed once daily for five consecutive days.

"The successful completion of this Phase I trial demonstrating the safety and tolerability of NGX426 when dosed over multiple days provides support for pursuing a Phase II program in chronic indications," said Ev Graham, Chief Executive Officer of TorreyPines. "Combined with the positive results from our recently completed Phase I study of NGX426 in a capsaicin induced pain model, we are very encouraged about the potential for NGX426 to treat both acute and chronic pain conditions."

The Phase I double-blind, placebo-controlled trial enrolled 20 healthy male and female subjects in sequential, dose-escalating cohorts. Subjects received once-daily oral doses of either 90 mg or 150 mg of NGX426 or placebo for five consecutive days, approximating exposure under steady-state pharmacokinetic conditions. Overall, NGX426 was well-tolerated. There were no dose-limiting adverse events or discontinuations from the study and reported adverse events were generally mild and transient.

NGX426, an ester prodrug, is an oral form of tezampanel, TorreyPines most advanced product candidate. Pharmacokinetic analyses from two Phase I studies confirmed that when given to humans, NGX426 is rapidly converted to tezampanel, the active moiety. To date, six Phase II, double-blind, placebo-controlled trials have demonstrated that tezampanel, administered either subcutaneously or intravenously, was more effective than placebo in relieving pain across migraine, nocic
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Max Muscle Introduces First-Ever Probiotics Protein Bar
2. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
3. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
4. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. World's First Website for Patients to Share Diagnostic-Quality Medical Images
7. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
8. BioComp Pharma Launches First Generic Drug for Tindamax(R)
9. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
10. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
11. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... May 4 Environmental Tectonics Corporation,s (NYSE AMEX ... Division announced today the addition of Mr. Ray ... Wyngarden will be responsible for expanding market awareness ... ETC,s other hyperbaric products in the western portion ...
... it has produced a synthetic H1N1 swine flu vaccine, Replikins PanFlu™, ... vaccine based on the same Replikins peptide technology which provided the ... was on its way. , ... London, UK (PRWEB) ...
... YORK and NASSAU, The Bahamas, May 1 Fincor ... Prospero Group (Pink Sheets: PRPG) , a leading company ... the new ACTRx Malaria and Dengue fever treatment. Fincor also ... a majority of ACTRx International Inc., which combines several natural ...
Cached Biology Technology:Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff 2Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff 3H1N1 Influenza "Swine Flu" Peptide Vaccine Now Available For Testing Worldwide 2Fincor (FINC) Makes a Share Transfer and Enters the Market With ACTRx a New Malaria and Dengue Fever Treatment 2
(Date:4/15/2014)... in nanoparticle form could help reduce side effects by ... years, scientists have developed nanoparticles that deliver one or ... to design particles that can carry any more than ... have devised a new way to build such nanoparticles, ... different drugs. In a paper published in the ...
(Date:4/15/2014)... cuttlefish, squid and octopus has uncovered details of ... they may help in investigating populations of their ... 10 new parasite species− dicyemid mesozoans −, which ... and octopus). They are the very first ... , "Although dicyemid parasites have been studied ...
(Date:4/14/2014)... swallow, but if you,re over 24 years of age ... cognitive motor performance, according to a new Simon Fraser ... doctoral student, associate professor Mark Blair, Thompson,s thesis supervisor, ... student, deliver the news in a just-published PLOS ... the first social science experiments to rest on big ...
Breaking Biology News(10 mins):Targeting cancer with a triple threat 2Targeting cancer with a triple threat 3Bizarre parasite may provide cuttlefish clues 2Study says we're over the hill at 24 2
... research has found that hurricane activity is ,clustered, rather ... ecosystems and human population. The research was carried ... Queensland Global Change Institute and School of Biological Sciences, ... Fellow) at the University of Exeter,s Exeter Climate Systems ...
... multi-disciplinary 5-year project at the University of Nevada, Reno ... $10 million in funding from the National Institutes of ... manipulate the communication between cells that causes human neurological ... of Medicine, the College of Science and the Department ...
... by researchers at The University of Texas at Austin ... a cure for Alzheimer,s disease and help answer one ... The research, led by Cockrell School of Engineering ... Assistant Professor Jon Pierce-Shimomura, aims to prevent degeneration of ...
Cached Biology News:Clustered hurricanes reduce impact on ecosystems 2$10 million grant supports biological sciences team at University of Nevada, Reno 2$10 million grant supports biological sciences team at University of Nevada, Reno 3Reversing aging 2Reversing aging 3Reversing aging 4
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Biology Products: